
Epidemiological studies indicate that Vitamin D has a beneficial, inhibitory effect on cancer development and subsequent progression, including melanoma (MM), and favourable MM outcome has been reported as directly related to vitamin D3 status, assessed by serum 25‐hydroxyvitamin D3 (25(OH)D3) levels taken at diagnosis. Therefore, it has been recommended that MM patients with deficient levels of 25(OH)D3 be given vitamin D3. This study examines the possible beneficial or detrimental effects of treating established cancer with vitamin D3. In animal models, having defective VDR signalling, vitamin D3 administration decreased survival and increased metastases. Work is needed to assess the integrity of tumour VDR signalling and the safety of vitamin D3 supplementation when defective.
Like
Save
Share